- Home
- Publications
- Publication Search
- Publication Details
Title
CYP3A activity: towards dose adaptation to the individual
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 12, Issue 5, Pages 479-497
Publisher
Informa Healthcare
Online
2016-03-08
DOI
10.1517/17425255.2016.1163337
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes
- (2015) Anne-Joy M. de Graan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans
- (2015) Nicolas Hohmann et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Addressing phenoconversion: the Achilles' heel of personalized medicine
- (2015) Rashmi R. Shah et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Use of Microdose Phenotyping to Individualise Dosing of Patients
- (2015) Nicolas Hohmann et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines forCYP3A5Genotype and Tacrolimus Dosing
- (2015) KA Birdwell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Proximal Roux-en-Y Gastric Bypass Alters Drug Absorption Pattern But Not Systemic Exposure of CYP3A4 and P-glycoprotein Substrates
- (2015) Lingtak-Neander Chan et al. PHARMACOTHERAPY
- Limited Sampling Strategy of Partial Area Under the Concentration–Time Curves to Estimate Midazolam Systemic Clearance for Cytochrome P450 3A Phenotyping
- (2015) Joanna C. Masters et al. THERAPEUTIC DRUG MONITORING
- Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects
- (2014) Sreeneeranj Kasichayanula et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers
- (2014) Margreke J. E. Brill et al. CLINICAL PHARMACOKINETICS
- Functional Gene Variants of CYP3A4
- (2014) A N Werk et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Response to “Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?”: Evaluation of CYP3A Activity With Microdoses of Midazolam
- (2014) N Hohmann et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Scientific Basis of Body Surface Area–Based Dosing
- (2014) E Chatelut et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents
- (2014) R Donald Harvey et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Quinine Compared to 4β-Hydroxycholesterol and Midazolam as Markers for CYP3A Induction by Rifampicin
- (2014) Linda Björkhem-Bergman et al. Drug Metabolism and Pharmacokinetics
- Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions
- (2014) Ben D. Snyder et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: Implications for diagnostic microdosing
- (2014) Gregory T. Wurz et al. INTERNATIONAL JOURNAL OF CANCER
- Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam
- (2014) Dorota Tomalik-Scharte et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Limited sampling strategies for tacrolimus exposure (AUC0-24) prediction after Prograf®and Advagraf®administration in children and adolescents with liver or kidney transplants
- (2014) Gonzalo N. Almeida-Paulo et al. TRANSPLANT INTERNATIONAL
- CYP3A4-Catalyzed Simvastatin Metabolism as a Non-Invasive Marker of Small Intestinal Health in Celiac Disease
- (2013) Belén Morón et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores
- (2013) Albader Albarmawi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer
- (2013) D. de Wit et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care
- (2013) Marianne K. DeGorter et al. Circulation-Cardiovascular Genetics
- Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study
- (2013) Jacqueline S. L. Kloth et al. CLINICAL PHARMACOKINETICS
- A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions
- (2013) B Halama et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance
- (2013) K-H Shin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance
- (2013) A N Werk et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate
- (2013) P. N. Morcos et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism
- (2013) Hylke de Jonge et al. PHARMACOGENOMICS
- Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem
- (2013) Kathrin Klein et al. Frontiers in Genetics
- Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation
- (2012) Ranjit K. Thirumaran et al. BIOCHEMICAL PHARMACOLOGY
- In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients
- (2012) H de Jonge et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effects of Ritonavir-Boosted Lopinavir on the Pharmacokinetics of Quinine
- (2012) M M Nyunt et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effects of Interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture
- (2012) Leslie J. Dickmann et al. CURRENT DRUG METABOLISM
- Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies
- (2012) Silke C. Mueller et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers
- (2012) Ellen Hulskotte et al. HEPATOLOGY
- Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation
- (2012) Anh N. Nguyen et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus
- (2011) Miroslav Dostalek et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer
- (2011) William C. Zamboni et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma
- (2011) Matthias Kroiss et al. CLINICAL ENDOCRINOLOGY
- Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil
- (2011) E D Kharasch et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo
- (2011) C-C Peng et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy
- (2011) S Katzenmaier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimal and Noninvasive Probes for Hepatic and First-Pass CYP3A Induction
- (2011) E D Kharasch et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis
- (2011) C Schmitt et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients
- (2011) C. J. Kirwan et al. INTENSIVE CARE MEDICINE
- A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan
- (2010) J. M. van der Bol et al. CLINICAL CANCER RESEARCH
- CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
- (2010) Henrik Gréen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A Holy Grail of Clinical Pharmacology: Prediction of Drug Pharmacokinetics and Pharmacodynamics in the Individual Patient
- (2009) L Z Benet CLINICAL PHARMACOLOGY & THERAPEUTICS
- Plasma 4β-Hydroxycholesterol: An Endogenous CYP3A Metric?
- (2009) D Tomalik-Scharte et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers
- (2009) Gopal Krishna et al. CLINICAL THERAPEUTICS
- Physicochemical Determinants of Human Renal Clearance
- (2009) Manthena V. S. Varma et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
- (2008) E Rouits et al. BRITISH JOURNAL OF CANCER
- The recovery time-course of CYP3A after induction by St John's wort administration
- (2008) Hiromitsu Imai et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping
- (2008) Joseph D. Ma et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information
- (2008) Yoshiyuki Ohno et al. CLINICAL PHARMACOKINETICS
- Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes
- (2008) RM Franke et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4
- (2008) Shu-Feng Zhou CURRENT DRUG METABOLISM
- Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions
- (2008) Jiansong Yang et al. CURRENT DRUG METABOLISM
- Challenges for drug studies in children: CYP3A phenotyping as example
- (2008) Saskia N. de Wildt et al. DRUG DISCOVERY TODAY
- Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A-Mediated Drug Interactions
- (2008) Scott R. Penzak et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Metabolic interactions of agrochemicals in humans
- (2008) Ernest Hodgson et al. PEST MANAGEMENT SCIENCE
- Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil
- (2003) R. Hyland et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search